Peer-reviewed veterinary case report
Combination of Bleomycin and Cytosine Arabinoside Chemotherapy for Relapsed Canine Lymphoma
- Journal:
- Journal of the American Animal Hospital Association
- Year:
- 2018
- Authors:
- Batschinski, Karen et al.
- Affiliation:
- From the Laboratory of Experimental and Comparative Oncology, Department of Pathology, School of Veterinary Medicine and Animal Sciences, University of São Paulo, Brazil, São Paulo, Brazil (K.B.); Department of Small Animal Clinical Sciences, Virginia–Maryland Regional College of Veterinary Medicine, Blacksburg, Virginia (N.D.); Oncology Department, VCA Veterinary Care Animal Hospital and Referral Center, Albuquerque, New Mexico (B.K.); and Oncology Department... · Brazil
- Species:
- dog
Abstract
ABSTRACT A retrospective study was performed to evaluate response rate, time to progression, and toxicity of a bleomycin and cytosine arabinoside (Bleo/Cytarabine) combination protocol for dogs with relapsed lymphoma (LSA). Dogs diagnosed with LSA and previously treated with chemotherapy were included in the study. A total of 20 dogs met the inclusion criteria, and 19 were evaluable for response. Bleomycin was administered subcutaneously on days 1 and 8 and cytosine arabinoside was administered subcutaneously on days 1–5 of a 21-day cycle. The median number of chemotherapy drugs given prior to the administration of Bleo/Cytarabine was 8.5. A total of 23 cycles of Bleo/Cytarabine were administered. The overall response rate was 36.8% (7 of 19 dogs had a partial response). The median time to progression was 15 days. Three dogs developed grade 3 thrombocytopenia and one dog had a grade 4 neutropenia. Bleo/Cytarabine had minor activity when used as a rescue therapy for pretreated LSA patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.5326/jaaha-ms-6617